LONDON (Alliance News) - AstraZeneca PLC's Novel Start trial for its Symbicort Turbuhaler demonstrated a reduction in the rate of asthma attacks in patients with mild asthma compared to common ...
LONDON (CBS.MW) -- AstraZeneca on Monday said that it received European Union approval for Symbicort Turbuhaler, which permits the use of an increased dose range in some patients with persistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results